New At-Home COVID test put to the test in 1,000-Person study
NCT ID NCT06744660
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks if a new COVID-19 test (Metrix COVID Test) works well when used at home or in clinics. About 1,000 people with COVID symptoms will take the test, and results will be compared to a standard FDA-cleared test. The goal is to see if the new test accurately detects the virus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participant or guardian understands and is able and willing to provide written informed consent, and assent where applicable, prior to study enrollment. 2. Male or female aged 2 years or older 3. Participant is currently exhibiting fever, or one or more symptoms of respiratory tract infection (such as, but not limited to, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea). Participant must still be exhibiting symptoms on the day of sample collection. 4. Participant or guardian agrees to read, and is able to read with understanding, the AN swab QRI prior to beginning the operation of each of the Metrix COVID-19 Test. 5. Participant or guardian is able and willing to contribute the required swab samples for testing and understands and is able and willing to sign the study informed consent. Exclusion Criteria: 1. Participant does not understand and/or is not able and willing to sign the study informed consent and/or assent. 2. Participant or guardian is not able to comply with nasal swab collection requirements following the QRI. 3. Participant has previously provided a sample for the study. 4. Participant is not able to tolerate sample collection. 5. Participant is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®). 6. Participants currently undergoing treatment and/or within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2. 7. Participants who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection. 8. Participants who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months. 9. Participants who do not understand/read the English language.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
AFC Madison
RECRUITINGMadison, Alabama, 35758, United States
Contact Email: •••••@•••••
-
AFC Montclair
RECRUITINGBirmingham, Alabama, 35210, United States
Contact Email: •••••@•••••
-
PPU Mid City
RECRUITINGBaton Rouge, Louisiana, 70802, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- When the immune system Can't fight back: tracking three respiratory viruses
- The household maze: how does COVID-19 move between family members?
- How does COVID-19 hit people born with weak immune systems?
- Can an oral drug stop COVID-19 from turning deadly?